Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6020 in Refractory Generalized Myasthenia Gravis
NCT06688435Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2025
- Primary completion
- Dec 2028
- Modality
- Small Interfering RNA (siRNA), CAR-T Cells, Antisense DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of SYS6020 in generalized myasthenia gravis (gMG) (7 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity at 12 months, Adverse Events and Serious Adverse Events at 12 months and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
SYS6020
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NCT06688435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06688435.